Anton Buzdin (AB) graduated from Moscow State University and defended PhD thesis in molecular biology at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. Since 2005, AB runs several research laboratories. AB also worked as CEO of several international biotech and biomed companies. AB authored 167 scientific papers and patent applications. AB team pioneered bioinformatic quantitative analysis of molecular pathways using transcriptomic or proteomic data, and developed several specialized algorithms and software packages to personalize prescription of proper target, immunotherapy or chemotherapy drugs to the patients that was clinically validated and commercialized (Oncobox/Oncofinder/iPanda). A bioinformatic method FLOWPS was developed to adopt machine learning algorithms to the analysis of gene expression and mutation data from the small cohorts of cancer patients. Shambhala technique was created to enable simultaneous harmonization of multiple gene expression platforms into a universal form. MiRImpact method is a unique tool to assess impact of whole microRNA profiles on molecular pathway activation. Watermelon Multisection is a new unique tool to quantitate quality of data clustering on dendrograms (~thousands of molecular profiles). AB team discovered multiple molecular markers of cancer. He authored several techniques in molecular biology for differential analysis of gene expression and of epigenetic landmarks. He discovered a new mechanism of RNA recombination in mammals and dissected molecular functions of numerous human genetic transposable elements. AB served as Chief Scientific Officer at Pathway Pharmaceuticals (Hong Kong), Insilico Medicine (USA) and Omicsway (USA).

Now AB heads several research laboratories, supervises 26 international employees and runs projects on molecular oncology, immunology and clinical bioinformatics at Sechenov First Moscow Medical University, Shemyakin-Ovchinnikov Institute, Moscow Institute of Physics and Technology, and Omicsway (USA). AB chairs a clinical trial NCT03724097 of transcriptomic-guided prescription of targeted therapeutics to advanced cancer patients using Oncobox platform. Since April 2021, AB serves as Chair of the Biostatistics and Bioinformatics subgroup, Pathobiology Group, European Organization for Research and Treatment of Cancer (EORTC), and is a Specialty Chief Editor (Cancer Genetics and Oncogenomics) of journal Frontiers in Genetics.